Pliant Therapeutics Set to Highlight Innovations in Healthcare

Pliant Therapeutics Participates in Prestigious Conference

Pliant Therapeutics, Inc. (NASDAQ: PLRX) has made an exciting announcement regarding its participation in a key industry event. Bernard Coulie, M.D., Ph.D., the company’s esteemed President and CEO, is set to present at the well-known Annual J.P. Morgan Healthcare Conference. This conference, an important gathering for healthcare professionals and investors alike, will take place soon, providing an excellent platform for Pliant to showcase their innovative approaches to fibrotic diseases.

The Opportunity to Present

Scheduled for January 14 at the Westin St. Francis Hotel, Dr. Coulie’s presentation will delve deeply into the advancements made by Pliant Therapeutics and its leading product candidate, bexotegrast. This oral small molecule has garnered attention for its dual selective inhibition capabilities, positioned to address critical health challenges such as idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).

A Closer Look at Bexotegrast

Bexotegrast stands out in Pliant Therapeutics' pipeline, exemplifying the company’s commitment to tackling fibrotic diseases with cutting-edge science. This candidate, designated PLN-74809, is engineered to inhibit specific integrins, playing a vital role in the fibrotic process. With Fast Track and Orphan Drug Designations from the U.S. FDA for both IPF and PSC, bexotegrast is at the forefront of Pliant’s innovative therapeutic strategies.

Recent Developments and Clinical Trials

Pliant is currently conducting an adaptive Phase 2b/3 trial named BEACON-IPF to assess the efficacy of bexotegrast in patients with IPF. This trial illustrates the company’s proactive approach to bringing transformative therapies to those in need. Furthermore, Pliant is exploring its other promising candidate, PLN-101095, which aims to inhibit integrins associated with solid tumors, further broadening the company’s impact in the oncology space.

Commitment to Innovation and Research

Pliant Therapeutics has made significant strides in the research arena, receiving clearance to initiate a Phase 1 study for PLN-101325, a monoclonal antibody designed to target muscular dystrophies. This level of innovation reinforces Pliant’s dedication to finding solutions that enhance patient outcomes and address unmet medical needs.

Connecting with Investors and Stakeholders

For those interested in Pliant’s developments, the live webcast of Dr. Coulie’s presentation will be accessible through the Investors & Media section on Pliant's official website. Moreover, a replay will be available for a month following the event, ensuring broad access to the information shared. Pliant Therapeutics remains committed to transparency and communication with stakeholders, reflecting its core values as a pioneering biopharmaceutical entity.

Follow Pliant’s Journey

Pliant Therapeutics invites the public to engage with its ongoing journey by connecting through various social media platforms. These channels provide updates on their progress, research findings, and corporate announcements, creating a robust dialogue with their audience.

Contact Information

Investor inquiries can be directed to Christopher Keenan, Vice President of Investor Relations and Corporate Communications. Interested parties can reach him at ir@pliantrx.com for any questions or additional information.

Frequently Asked Questions

1. What is the significance of the J.P. Morgan Healthcare Conference for Pliant Therapeutics?

The conference is a prestigious platform for Pliant Therapeutics to present its innovations and engage with key industry stakeholders, showcasing its commitment to improving healthcare.

2. What is bexotegrast and why is it important?

Bexotegrast is Pliant's lead product candidate targeting fibrotic diseases, specifically IPF and PSC, and has received important designations from regulatory bodies to expedite its development.

3. How is Pliant Therapeutics addressing fibrotic diseases?

Pliant is developing innovative therapies such as bexotegrast and PLN-101095 that target the underlying mechanisms of fibrotic diseases, aiming to improve patient outcomes significantly.

4. How can investors learn more about Pliant’s progress?

Investors can access updates and information through the Investors & Media section on Pliant's website and follow their social media channels for real-time updates.

5. Who can be contacted for investor relations inquiries?

Christopher Keenan, Vice President of Investor Relations, is the main contact for investor inquiries and can be reached via email at ir@pliantrx.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.